AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 4 - (NewsRx.com & NewsRx.net) -- Scientists have identified an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.
According to recent research from the United States, "Accumulating evidence supports the requirement for both tumor-specific CD8+ and CD4+ T cell responses for efficient tumor rejection to occur. Because of its expression in different tumor types, the cancer/testis antigen encoded by the synovial sarcoma X breakpoint 2 (SSX-2) gene is among the most relevant candidates for the development of generic cancer vaccines. The immunogenicity of SSX-2 has been previously corroborated by detection of specific humoral and CD8+ T cell responses in cancer patients."
"In this study, we report identification of the first CD4+ T cell epitope encoded by SSX-2," stated Maha Ayyoub at Columbia University and collaborators in the United States and Switzerland. "The identified epitope mapped to the 19-34 region of the protein and was recognized by CD4+ T cells from an antigen-expressing melanoma patient in association with HLADPBI*0101. The absence of detectable response in healthy donors and other patients suggests that SSX-2-specific CD4+ T cells in the responder patient had been previously expanded in vivo in response to the autologous tumor."
"The epitope did not appear to be presented on ...